BR112021008139A2 - métodos para tratar doença de alzheimer - Google Patents
métodos para tratar doença de alzheimer Download PDFInfo
- Publication number
- BR112021008139A2 BR112021008139A2 BR112021008139-9A BR112021008139A BR112021008139A2 BR 112021008139 A2 BR112021008139 A2 BR 112021008139A2 BR 112021008139 A BR112021008139 A BR 112021008139A BR 112021008139 A2 BR112021008139 A2 BR 112021008139A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta
- hydroxypropyl
- cyclodextrin
- dose
- month
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752131P | 2018-10-29 | 2018-10-29 | |
| US62/752,131 | 2018-10-29 | ||
| US201962885053P | 2019-08-09 | 2019-08-09 | |
| US62/885,053 | 2019-08-09 | ||
| PCT/US2019/057784 WO2020092107A1 (en) | 2018-10-29 | 2019-10-24 | Methods for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021008139A2 true BR112021008139A2 (pt) | 2021-08-03 |
Family
ID=68583503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021008139-9A BR112021008139A2 (pt) | 2018-10-29 | 2019-10-24 | métodos para tratar doença de alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11925659B2 (https=) |
| EP (1) | EP3873604B1 (https=) |
| JP (1) | JP7446322B2 (https=) |
| KR (1) | KR20210084480A (https=) |
| CN (1) | CN112996562A (https=) |
| BR (1) | BR112021008139A2 (https=) |
| CA (1) | CA3114021C (https=) |
| ES (1) | ES2992137T3 (https=) |
| PT (1) | PT3873604T (https=) |
| WO (1) | WO2020092107A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| CN113490691A (zh) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | 环糊精二聚体、其组合物及其用途 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP4157290A4 (en) * | 2020-06-02 | 2024-06-05 | National University of Singapore | COMPOSITIONS, THEIR USES IN THERAPY AND METHODS THEREFOR |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| WO2022099094A1 (en) * | 2020-11-06 | 2022-05-12 | Eip Pharma, Inc. | Compositions and methods for treating depression |
| EP4240486A4 (en) * | 2020-11-06 | 2024-05-22 | EIP Pharma, Inc. | TREATMENT OF GALKING DYSFUNCTION IN THE CONTEXT OF A NEURODEGENERATIVE DISEASE |
| US12285440B2 (en) | 2021-03-14 | 2025-04-29 | Massachusetts Institute Of Technology | APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia |
| WO2023089062A1 (en) * | 2021-11-18 | 2023-05-25 | Vib Vzw | Improved gamma-secretase inhibitor screening assays |
| WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
| WO2023191425A1 (ko) * | 2022-03-28 | 2023-10-05 | 주식회사 비엔에이치리서치 | 약물의 전기생리학적 스크리닝 방법 |
| CN114569742B (zh) * | 2022-05-09 | 2022-07-19 | 北京剂泰医药科技有限公司 | 一种组合物及其制备方法和应用 |
| CA3259307A1 (en) * | 2022-06-13 | 2023-12-21 | Beren Therapeutics P.B.C. | SYSTEMS AND METHODS FOR MANUFACTURING HYDROXYPROPYL-BETA-CYCLODEXTRIN |
| EP4561566A1 (en) * | 2022-07-29 | 2025-06-04 | Anavex Life Sciences Corp. | Compositions and methods for prevention of cognitive decline caused by degenerative diseases |
| KR20250073473A (ko) * | 2022-09-30 | 2025-05-27 | 싸이클로 테라퓨틱스, 아이엔씨. | 조기 알츠하이머병 치료 방법 |
| WO2025214478A1 (zh) * | 2024-04-12 | 2025-10-16 | 北京华昊中天生物医药股份有限公司 | 一种优替德隆药物组合物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| US5569756A (en) | 1995-03-21 | 1996-10-29 | American Maize-Products Company | Purification of chemically modified cyclodextrins |
| US8883494B2 (en) | 2003-11-14 | 2014-11-11 | Adil A. KHAN | In vitro model for neuronal death |
| CN101674842A (zh) | 2007-03-02 | 2010-03-17 | 普瑞芬医药有限公司 | 治疗阿尔茨海默氏病和痴呆的组合物和方法 |
| MX371073B (es) | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
| CN107865968B (zh) | 2012-08-03 | 2021-03-05 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗溶酶体贮积症的环糊精 |
| FR3014694B1 (fr) | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| US10413517B2 (en) | 2014-06-12 | 2019-09-17 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス， インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
| US20200000840A1 (en) * | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
-
2019
- 2019-10-24 BR BR112021008139-9A patent/BR112021008139A2/pt unknown
- 2019-10-24 PT PT198054397T patent/PT3873604T/pt unknown
- 2019-10-24 ES ES19805439T patent/ES2992137T3/es active Active
- 2019-10-24 CN CN201980071651.0A patent/CN112996562A/zh active Pending
- 2019-10-24 JP JP2021547654A patent/JP7446322B2/ja active Active
- 2019-10-24 CA CA3114021A patent/CA3114021C/en active Active
- 2019-10-24 KR KR1020217013055A patent/KR20210084480A/ko not_active Ceased
- 2019-10-24 US US17/289,137 patent/US11925659B2/en active Active
- 2019-10-24 WO PCT/US2019/057784 patent/WO2020092107A1/en not_active Ceased
- 2019-10-24 EP EP19805439.7A patent/EP3873604B1/en active Active
-
2024
- 2024-01-29 US US18/425,707 patent/US20240415871A1/en not_active Abandoned
-
2025
- 2025-06-09 US US19/232,726 patent/US20250302864A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112996562A (zh) | 2021-06-18 |
| EP3873604B1 (en) | 2024-08-21 |
| CA3114021A1 (en) | 2021-05-07 |
| KR20210084480A (ko) | 2021-07-07 |
| WO2020092107A1 (en) | 2020-05-07 |
| US20220008453A1 (en) | 2022-01-13 |
| JP2022509358A (ja) | 2022-01-20 |
| EP3873604A1 (en) | 2021-09-08 |
| CA3114021C (en) | 2025-05-27 |
| ES2992137T3 (es) | 2024-12-09 |
| JP7446322B2 (ja) | 2024-03-08 |
| PT3873604T (pt) | 2024-10-22 |
| US11925659B2 (en) | 2024-03-12 |
| US20240415871A1 (en) | 2024-12-19 |
| US20250302864A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021008139A2 (pt) | métodos para tratar doença de alzheimer | |
| Akhtar et al. | Preclinical models for Alzheimer’s disease: past, present, and future approaches | |
| TW202015742A (zh) | 投遞腺相關病毒（ａａｖ）之組成物和方法 | |
| KR20200085837A (ko) | 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도 | |
| Chen et al. | Defective autophagy and mitophagy in Alzheimer’s disease: mechanisms and translational implications | |
| KR20150002681A (ko) | App 특이적 bace 억제제(asbi) 및 이의 용도 | |
| Zhang et al. | Dietary flavonoid chrysin functions as a dual modulator to attenuate amyloid-β and tau pathology in the models of Alzheimer’s disease | |
| Choe et al. | The novel sphingolipids cP1P and P1P attenuate neuroinflammation and enhance S1PR1/Akt/mTOR signaling to mitigate cognitive decline in an Alzheimer’s disease mouse model | |
| US20250339422A1 (en) | Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6 | |
| Lin et al. | ACLY regulates autolysosome acidification through tubulin acetylation‐mediated assembly of V‐ATPase subunits in Alzheimer's disease model mice | |
| Zhu et al. | Targeting glial dysfunction in Alzheimer’s disease: insights into pathogenesis and emerging therapeutics | |
| CN120051284A (zh) | 用于治疗早期阿尔茨海默病的方法 | |
| Richardson et al. | Chronic intracerebroventricular infusion of lipopolysaccharide: effects of ibuprofen treatment and behavioural and histopathological correlates | |
| Jain | Neuroprotection in Alzheimer disease | |
| EP4590304A1 (en) | Methods of reducing neurodegeneration associated with neurodegenerative diseases | |
| HK40059055A (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| HK40059055B (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| US20260124236A1 (en) | Methods for treating early alzheimer’s disease | |
| CA3268619A1 (en) | Methods for treating early alzheimer's disease | |
| Zhu et al. | Targeting glial dysfunction in Alzheimer’s disease: insights into pathogenesis and emerging | |
| Artíguez Calvo | Exploring Alzheimer’s disease: current knowledge and future perspectives | |
| Growdon | Acetylcholine in AD: Expectations meet reality | |
| Bhattacharya | Current state of tau aggregation inhibitors | |
| Masnata et al. | The prion-like properties of the mutant huntingtin protein: demonstration in in vitro and in vivo systems Thèse Maria Masnata Doctorat en neurobiologie | |
| Hettinger | The Regulation of Extracellular Amyloid-β Levels by Ionotropic Glutamatergic Transmission in an Alzheimer's Disease Mouse Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |